OUR PORTFOLIO

Our portfolio includes grants and mission-related investments supporting Alzheimer’s drugs in development, biomarkers, prevention programs, and other projects designed to build the capacity of the field. You can explore the programs we have supported using the filter and “Search Database” options in the sidebar.

All Filters

To reveal more filter options, please select whether you would like to review Active or Closed projects:

Clear
Organization: reMYND

1 Projects | 1 Researchers | $4,122,340 Invested

2026

reMYND

Gerard Griffioen, PhD

A Randomized phase 1b trial to evaluate the therapeutic efficacy of septin glue REM392 in mild-to-moderate AD patients.

  • Funding Amount: $4,122,340
  • Organization Type: Biotechnology/For Profit
  • Program: Clinical
  • Target: Synaptic Plasticity/Neuroprotection
  • Status: Active